Martin Laimer

Martin Laimer serves as Associate Professor and 1st senior physician at Paracelsus Medical University in Salzburg, Austria, with dual appointments in the Department of Dermatology and Allergology and the Research Program of Molecular Therapy of Genodermatoses. His clinical and research work focuses on rare genetic skin disorders, particularly various forms of epidermolysis bullosa. With over 179 research outputs spanning more than two decades, he has established himself as a leading expert in the field of genodermatoses and rare skin diseases.

Dr. Laimer's research interests center on clinical trials for rare dermatological conditions, molecular therapies for epidermolysis bullosa, and the challenges of conducting research on ultra-rare diseases. His work addresses critical issues in trial design, patient recruitment, and treatment efficacy for conditions affecting small patient populations. He has particular expertise in epidermolysis bullosa simplex, epidermolysis bullosa dystrophica, and associated squamous cell carcinoma.

His recent publications demonstrate a consistent focus on advancing clinical trial methodologies for rare diseases, with significant contributions to understanding treatment approaches for epidermolysis bullosa variants. His research spans molecular genetics, clinical dermatology, and therapeutic interventions, with an emphasis on translating basic science discoveries into clinical applications.

Dr. Laimer has led multiple research projects, including EB Clinical Research initiatives in 2019 and 2022 as principal investigator, and served as co-principal investigator for a dual-center phase II trial on losartan for recessive dystrophic EB. His collaborative work extends to statistical methodology development for rare disease trials, reflecting his commitment to improving research approaches in this challenging field.

As an active contributor to the academic community, Dr. Laimer has organized significant conferences including the ÖADF Summer School in 2023 and the 5th Austrian Congress for Rare Diseases in 2015. His leadership in these events underscores his role as a central figure in advancing rare disease research and clinical practice in Austria.